Close

Wedbush Boosts Target on Outperform-Rated Oncothyreon (ONTY) to $31 Ahead of STIMUVAX Phase III Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. BA
7. HCP
8. SNAP
9. TMUS
10. MSFT


Go back to Wedbush Boosts Target on Outperform-Rated Oncothyreon (ONTY) to $31 Ahead of STIMUVAX Phase III Data